These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21455068)

  • 1. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
    Hyland M; Rudick RA
    Curr Opin Neurol; 2011 Jun; 24(3):255-61. PubMed ID: 21455068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
    Zivadinov R
    Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
    Rudick RA; Cutter G; Reingold S
    Mult Scler; 2002 Oct; 8(5):359-65. PubMed ID: 12356200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine and methotrexate in multiple sclerosis.
    Fernández O; Fernández V; De Ramón E
    J Neurol Sci; 2004 Aug; 223(1):29-34. PubMed ID: 15261557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
    Ozawa K; Saida T
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.
    Tavazzi E; Dwyer MG; Weinstock-Guttman B; Lema J; Bastianello S; Bergamaschi R; Cosi V; Benedict RH; Munschauer FE; Zivadinov R
    Neuroimage; 2007 Jul; 36(3):746-54. PubMed ID: 17498974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
    Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.